Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015, Article ID 732539, 5 pages
http://dx.doi.org/10.1155/2015/732539
Research Article

Relationship between Prolactin Plasma Levels and White Matter Volume in Women with Multiple Sclerosis

1Department of Neurology and Psychiatry, Sapienza University of Rome, 00185 Rome, Italy
2Sant’Andrea Hospital, 00189 Rome, Italy
3Italian National Agency for New Technologies, Energy and Sustainable Economic Development (ENEA), 00196 Rome, Italy
4Institute of Psychological Medicine and Clinical Neurosciences, Cardiff University School of Medicine, Cardiff CF14 4XN, UK
5IRCCS Fondazione Santa Lucia, 00142 Rome, Italy
6IRCCS Neuromed, Pozzilli, 86077 Isernia, Italy

Received 13 January 2015; Revised 17 June 2015; Accepted 22 June 2015

Academic Editor: Luc Vallières

Copyright © 2015 L. De Giglio et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Correale, M. F. Farez, and M. C. Ysrraelit, “Role of prolactin in B cell regulation in multiple sclerosis,” Journal of Neuroimmunology, vol. 269, no. 1-2, pp. 76–86, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Gregg, “Pregnancy, prolactin and white matter regeneration,” Journal of the Neurological Sciences, vol. 285, no. 1-2, pp. 22–27, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Costanza, S. Musio, M. Abou-Hamdan, N. Binart, and R. Pedotti, “Prolactin is not required for the development of severe chronic experimental autoimmune encephalomyelitis,” The Journal of Immunology, vol. 191, no. 5, pp. 2082–2088, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Costanza, N. Binart, L. Steinman, and R. Pedotti, “Prolactin: a versatile regulator of inflammation and autoimmune pathology,” Autoimmunity Reviews, vol. 14, no. 3, pp. 223–230, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Markianos, G. Koutsis, M. E. Evangelopoulos, D. Mandellos, and C. Sfagos, “Serum and cerebrospinal fluid prolactin levels in male and female patients with clinically-isolated syndrome or relapsing-remitting multiple sclerosis,” Journal of Neuroendocrinology, vol. 22, no. 6, pp. 503–508, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. M. H. Harirchian, M. A. Sahraian, and A. Shirani, “Serum prolactin level in patients with multiple sclerosis: a case control study,” Medical Science Monitor, vol. 12, no. 4, pp. CR177–CR180, 2006. View at Google Scholar · View at Scopus
  7. S. Moshirzadeh, K. Ghareghozli, A. A. Harandi, and H. Pakdaman, “Serum prolactin level in patients with relapsing-remitting multiple sclerosis during relapse,” Journal of Clinical Neuroscience, vol. 19, no. 4, pp. 622–623, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Yamasaki, I. Horiuchi, M. Minohara et al., “Hyperprolactinemia in optico-spinal multiple sclerosis,” Internal Medicine, vol. 39, no. 4, pp. 296–299, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. F. Then Berg, T. Kümpfel, E. Schumann et al., “Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis—reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations,” BMC Neurology, vol. 6, article 19, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. W. I. McDonald, A. Compston, G. Edan et al., “Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis,” Annals of Neurology, vol. 50, no. 1, pp. 121–127, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. J. F. Kurtzke, “Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS),” Neurology, vol. 33, no. 11, pp. 1444–1452, 1983. View at Publisher · View at Google Scholar · View at Scopus
  12. S. M. Smith, Y. Zhang, M. Jenkinson et al., “Accurate, robust, and automated longitudinal and cross-sectional brain change analysis,” NeuroImage, vol. 17, no. 1, pp. 479–489, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. S. M. Smith, M. Jenkinson, M. W. Woolrich et al., “Advances in functional and structural MR image analysis and implementation as FSL,” NeuroImage, vol. 23, no. 1, pp. S208–S219, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Zhornitsky, V. W. Yong, S. Weiss, and L. M. Metz, “Prolactin in multiple sclerosis,” Multiple Sclerosis, vol. 19, no. 1, pp. 15–23, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. V. Nociti, G. Frisullo, T. Tartaglione et al., “Multiple sclerosis attacks triggered by hyperprolactinemia,” Journal of Neuro-Oncology, vol. 98, no. 3, pp. 407–409, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Gregg, V. Shikar, P. Larsen et al., “White matter plasticity and enhanced remyelination in the maternal CNS,” The Journal of Neuroscience, vol. 27, no. 8, pp. 1812–1823, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Johnson, H. Mowbray, B. Verhaeghe et al., “Assessing the safety and efficacy of prolactin in EAE: a step towards a clinical trial of prolactin in multiple sclerosis,” Multiple Sclerosis Journal, vol. 15, pp. S151–S269, 2009. View at Google Scholar
  18. S. Zhornitsky, T. A. Johnson, L. M. Metz, S. Weiss, and V. W. Yong, “Prolactin in combination with interferon-β reduces disease severity in an animal model of multiple sclerosis,” Journal of Neuroinflammation, vol. 12, article 55, 2015. View at Publisher · View at Google Scholar
  19. J.-I. Kira, M. Harada, Y. Yamaguchi, N. Shida, and I. Goto, “Hyperprolactinemia in multiple sclerosis,” Journal of the Neurological Sciences, vol. 102, no. 1, pp. 61–66, 1991. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Watad, M. Versini, P. Y. Jeandel, H. Amital, and Y. Shoenfeld, “Treating prolactinoma can prevent autoimmune diseases,” Cellular Immunology, vol. 294, no. 2, pp. 84–86, 2015. View at Publisher · View at Google Scholar